Pathway activation mapping of c-MET inhibitor effects in high-and... | Download Scientific Diagram
Molecules | Free Full-Text | Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
The role of MET in chemotherapy resistance | Oncogene
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges: Trends in Molecular Medicine
Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - ScienceDirect
Tivantinib (ARQ 197) | 99.65%(HPLC) | In Stock | c-Met inhibitor
AMG-458 is a Selective and Orally Bioavailable c-Met Inhibitor - Network of Cancer Research
c-Met inhibitor - Wikipedia
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer | Science Translational Medicine
Frontiers | Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
c-Met inhibitor - Wikipedia
c-Met inhibitor 1 | c-Met/HGFR Inhibitor | MedChemExpress
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Recent advances in the discovery of small molecule c-Met Kinase inhibitors - ScienceDirect
Trends in the development of MET inhibitors for hepatocellular carcinoma | Future Oncology
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced NSCLC
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Glumetinib (SCC244) | 99.87%(HPLC) | In Stock | c-Met inhibitor
APExBIO - PHA-665752|C-Met inhibitor,potent and ATP-competitive|CAS# 477575-56-7
c-Met inhibitor - Wikipedia
Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways - ScienceDirect
